通化金马：拟投资7000.00万元设立全资子公司

Core Viewpoint - The company plans to invest CNY 70 million to establish a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd., to enhance its capabilities in the innovative pharmaceutical sector and align with its strategic transformation towards a modern, innovation-driven pharmaceutical enterprise [1] Investment Details - The investment amount is CNY 70 million, which will be sourced from the company's own or raised funds [1] - The registered capital of the new subsidiary will also be CNY 70 million [1] - The location of the new subsidiary is in Guilin City, specifically in the Lingui District [1] Strategic Intent - The investment aims to strengthen mergers and acquisitions in the innovative drug industry and optimize the company's industrial layout [1] - This move is in line with the company's strategic planning to transition into an innovation-driven modern pharmaceutical enterprise [1] Approval and Compliance - The investment has undergone the necessary board approval process and does not require shareholder meeting review [1] - The transaction does not constitute a related party transaction or a major asset restructuring [1] Future Considerations - The newly established company has not yet completed its business registration, indicating that future revenue remains uncertain [1] - The company plans to enhance its management mechanisms to mitigate risks associated with this investment [1]